With an increasingly profound understanding of the interplay between condensate biology and diseases, there is a poised acceleration of classical drug development processes, catalyzing breakthroughs ...
DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation ...
Dewpoint Therapeutics, Inc., a biotechnology company pioneering condensate-modulating therapeutics, today announced the ...
Genetic engineers can design and assemble sophisticated gene circuits to program cells with new functions, but important signaling molecules can become diluted as these cells grow and divide, causing ...
Researchers led by Prof. XU Zhiheng from the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences, revealed the important roles of POSH phase separation and its ...
Dewpoint Therapeutics doses first patient in phase 1a/2a clinical trial of DPTX3186 to treat advanced solid tumours: Boston Monday, February 9, 2026, 18:00 Hrs [IST] Dewpoint Ther ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results